Maternal Obesity May Up Risk for Future Liver Disease in Offspring

TUESDAY, July 27, 2021 -- There is a strong association between maternal weight and future nonalcoholic fatty liver disease (NAFLD) in offspring, according to a study published online July 18 in the Journal of Hepatology. Hannes Hagström,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Maria Sotiropoulou, Ioannis Katsaros, Michail Vailas, Irene Lidoriki, George V Papatheodoridis, Nikolaos G Kostomitsopoulos, Georgia Valsami, Alexandra Tsaroucha, Dimitrios SchizasSaudi Journal of Gastroenterology 2021 27(6):319-330Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease, affecting almost one-third of the general population and 75% of obese patients with type 2 diabetes. The aim of this article is to review the current evidence concerning the role of quercetin, a natural compound and flavonoid, and its possible therapeutic effects on this modern-day disease. Despite the...
Source: The Saudi Journal of Gastroenterology - Category: Gastroenterology Authors: Source Type: research
Metabolic Syndrome and Related Disorders, Ahead of Print.
Source: Metabolic Syndrome and Related Disorders - Category: Endocrinology Authors: Source Type: research
Conditions:   Non-Alcoholic Fatty Liver Disease;   Fatty Liver, Nonalcoholic;   Obesity Intervention:   Behavioral: Mindfulness Based Stress Reduction (MBSR) Sponsor:   Virginia Commonwealth University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: Our novel findings support the potential use of SP-1154 as a therapeutic drug for obesity and its related NAFLD by targeting the inflamed VAT.PMID:34813997 | DOI:10.1016/j.biopha.2021.112441
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Source Type: research
Endocr J. 2021 Nov 19. doi: 10.1507/endocrj.EJ21-0563. Online ahead of print.ABSTRACTFatty liver index (FLI) calculated by using body mass index (BMI), waist circumference and levels of γ-glutamyl transferase and triglycerides is a non-invasive predictor of nonalcoholic fatty liver disease (NAFLD). The original study in Italy showed that the cutoff level for prediction of NAFLD was FLI ≥60. However, the sex difference in FLI was not taken into consideration, and it is unclear whether the cutoff value can be applied to other races. We investigated the cutoff value of FLI for prediction of NAFLD determined by abdomi...
Source: Endocrine Journal - Category: Endocrinology Authors: Source Type: research
Biochem Biophys Res Commun. 2021 Nov 16;585:169-176. doi: 10.1016/j.bbrc.2021.11.038. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) is frequently associated with obesity, insulin resistance, and endoplasmic reticulum (ER) stress. Elevated circulating levels of the hepatokine leukocyte cell-derived chemotaxin-2 (LECT2) have also been noted in NAFLD; however, the mechanism underlying this association is unclear. To investigate a possible link between ER stress/unfolded protein response (UPR) signaling and LECT2 secretion, HepG2 cells were incubated with ER stress inducers with or without an ER stres...
Source: Cell Research - Category: Cytology Authors: Source Type: research
Endocr J. 2021 Nov 19. doi: 10.1507/endocrj.EJ21-0563. Online ahead of print.ABSTRACTFatty liver index (FLI) calculated by using body mass index (BMI), waist circumference and levels of γ-glutamyl transferase and triglycerides is a non-invasive predictor of nonalcoholic fatty liver disease (NAFLD). The original study in Italy showed that the cutoff level for prediction of NAFLD was FLI ≥60. However, the sex difference in FLI was not taken into consideration, and it is unclear whether the cutoff value can be applied to other races. We investigated the cutoff value of FLI for prediction of NAFLD determined by abdomi...
Source: Endocrine Journal - Category: Endocrinology Authors: Source Type: research
Biochem Biophys Res Commun. 2021 Nov 16;585:169-176. doi: 10.1016/j.bbrc.2021.11.038. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) is frequently associated with obesity, insulin resistance, and endoplasmic reticulum (ER) stress. Elevated circulating levels of the hepatokine leukocyte cell-derived chemotaxin-2 (LECT2) have also been noted in NAFLD; however, the mechanism underlying this association is unclear. To investigate a possible link between ER stress/unfolded protein response (UPR) signaling and LECT2 secretion, HepG2 cells were incubated with ER stress inducers with or without an ER stres...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Source Type: research
rsquo;Beirne Non-alcoholic fatty liver disease (NAFLD) is becoming the leading cause of liver morbidity worldwide and, as such, represents the pathogenic background for the increasing incidence of hepatocellular carcinoma (HCC). The annual incidence of NAFLD-related HCC is expected to increase by 45–130% by 2030. Diabetes mellitus is the most important risk factor for HCC development in NAFLD, with the risk further increased when associated with other metabolic traits, such as obesity, arterial hypertension and dyslipidemia. The highest risk of HCC exists in patients with advanced fibrosis or cirrhosis, although ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Biomed Pharmacother. 2021 Dec;144:112357. doi: 10.1016/j.biopha.2021.112357. Epub 2021 Oct 28.ABSTRACTHigher global prevalence of non-alcoholic fatty liver disease (NAFLD) is associated with obesity, steatosis, and insulin resistance (IR), and often progresses to steatohepatitis (NASH). Even after more than twenty years of research, there is still no FDA approved therapy for the treatment of fatty liver disease/NASH though, Saroglitazar - a dual PPAR α/γ agonist has been recently approved as a therapeutic option for the fatty liver disease in India. Hepatoprotective Ayurvedic formulations are widely used and ar...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Eating Disorders & Weight Management | Fatty Liver Disease (FLD) | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Pharmaceuticals | Study | Urology & Nephrology